NCT06760156View on ClinicalTrials.gov

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

PHASE2RecruitingINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions

Large B-cell Lymphoma

Interventions

DRUG

Tafasitamab

The recommended dose of tafasitamab is 12 mg/kg.

DRUG

Lenalidomide

The starting dose for lenalidomide will be 25 mg PO daily.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT06760156 - Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym | Biotech Hunter | Biotech Hunter